Dachaigh › Carcinoma Nasopharyngeal
Sgrùdaidhean clionaigeach Carcinoma Nasopharyngeal a’ fastadh anns na SA
Tha 13 sgrùdaidhean airson Carcinoma Nasopharyngeal a’ fastadh phàirtichean aig làraichean air feadh nan Stàitean Aonaichte.
Bailtean leis na sgrùdaidhean as motha
- Atlanta, GA6 sgrùdaidhean
- Cincinnati, OH3 sgrùdaidhean
- Washington, DC3 sgrùdaidhean
- Oklahoma City, OK3 sgrùdaidhean
- Houston, TX3 sgrùdaidhean
- Pittsburgh, PA3 sgrùdaidhean
- Richmond, VA3 sgrùdaidhean
- Chicago, IL3 sgrùdaidhean
- Milwaukee, WI3 sgrùdaidhean
- San Francisco, CA3 sgrùdaidhean
- Los Angeles, CA3 sgrùdaidhean
- Charlotte, NC3 sgrùdaidhean
Le stàit
- California6 sgrùdaidhean
- Georgia6 sgrùdaidhean
- Illinois3 sgrùdaidhean
- Maryland3 sgrùdaidhean
- Missouri3 sgrùdaidhean
- North Carolina3 sgrùdaidhean
- Ohio3 sgrùdaidhean
- Oklahoma3 sgrùdaidhean
- Pennsylvania3 sgrùdaidhean
- South Carolina3 sgrùdaidhean
- Texas4 sgrùdaidhean
- Virginia4 sgrùdaidhean
- Wisconsin3 sgrùdaidhean
Sgrùdaidhean air an ùrachadh o chionn ghoirid
Teacsa sgrùdaidh oifigeil (Beurla)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
A’ fastadhÌre 1
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06479811Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
A’ fastadhÌre 2
Suas gu aois 21 · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06064097Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT06532279A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT07749586Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Iuch 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Iuch 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Ògmh 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Ògmh 2026 · NCT06682442Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Gibl 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Màrt 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Gearr 2026 · NCT06636734Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.